Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Abrocitinib by Pfizer for Dermatological Disorders: Likelihood of Approval
Abrocitinib is under clinical development by Pfizer and currently in Phase II for Dermatological Disorders. According to GlobalData, Phase II...
Data Insights
Abrocitinib by Pfizer for Pruritus: Likelihood of Approval
Abrocitinib is under clinical development by Pfizer and currently in Phase II for Pruritus. According to GlobalData, Phase II drugs...